Best Supplements for Reduced Hospitalization Duration
Ranked by research evidence. Compare 3 supplements across 7 papers from the biomedical literature, with effect direction, evidence strength, and dose range for each.
Top picks by evidence
- Moderate evidence3 studies
Across 3 studies (2 meta-analyses and 1 RCT), all reported beneficial effects of Lactobacillus reuteri on reducing hospitalization duration. Effect sizes were mixed (small to large): a large reduction (−10.77 days) was observed in preterm neonates, while smaller reductions (−0.54 days) were seen in children with acute gastroenteritis. Two of the three studies were statistically significant; no specific dose or form was consistently reported.
- Low evidence3 studies
Across 3 studies, all reported beneficial effects of Lactobacillus reuteri UALre-16 on reducing hospitalization duration, with effect sizes ranging from small to large. Two of the three studies found statistically significant reductions. The primary studied populations were children with acute gastroenteritis and preterm neonates, though doses and study durations were not consistently reported.
Top combinations for Reduced Hospitalization Duration
most supplement research is combination research- Low evidence
All 3 studies of the combination (Lactobacillus reuteri MAK02L14R and Lactobacillus reuteri UALre-16) reported beneficial effects on reducing hospitalization duration, with 2 of 3 reaching statistical significance. Effect sizes were mixed (small in children with acute gastroenteritis, large in preterm neonates), and the evidence mirrors the solo syntheses for each strain, which show similar mixed effects across the same populations. The combination does not appear to demonstrate stronger effects than either strain alone, but the studies test the probiotics as single strains (DSM 17938) rather than a true combination, so no synergy or additivity can be inferred.
- ModerateLactobacillus reuteri MAK02L14RAcross 3 studies (2 meta-analyses and 1 RCT), all reported beneficial effects of Lactobacillus reuteri on reducing hospitalization duration. Effect sizes were mixed (small to large): a large reduction (−10.77 days) was observed in preterm neonates, while smaller reductions (−0.54 days) were seen in children with acute gastroenteritis. Two of the three studies were statistically significant; no specific dose or form was consistently reported.3 beneficial3 studies
- LowLactobacillus reuteri UALre-16Across 3 studies, all reported beneficial effects of Lactobacillus reuteri UALre-16 on reducing hospitalization duration, with effect sizes ranging from small to large. Two of the three studies found statistically significant reductions. The primary studied populations were children with acute gastroenteritis and preterm neonates, though doses and study durations were not consistently reported.3 beneficial3 studies